Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

A novel genetic and morphologic phenotype of ARID2-mediated myelodysplasia

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

References

  1. Corey SJ, Minden MD, Barber DL, Kantarjian H, Wang JC, Schimmer AD . Myelodysplastic syndromes: the complexity of stem-cell diseases. Nat Rev Cancer 2007; 7: 118–129.

    Article  CAS  PubMed  Google Scholar 

  2. Haferlach T, Nagata Y, Grossmann V, Okuno Y, Bacher U, Nagae G et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia 2014; 28: 241–247.

    Article  CAS  PubMed  Google Scholar 

  3. Papaemmanuil E, Gerstung M, Malcovati L, Tauro S, Gundem G, Van Loo P et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood 2013; 122: 3616–3627.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Makishima H, Yoshizato T, Yoshida K, Sekeres MA, Radivoyevitch T, Suzuki H et al. Dynamics of clonal evolution in myelodysplastic syndromes. Nat Genet 2017; 49: 204–212.

    Article  CAS  PubMed  Google Scholar 

  5. Li M, Zhao H, Zhang X, Wood LD, Anders RA, Choti MA et al. Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma. Nat Genet 2011; 43: 828–829.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Hodis E, Watson IR, Kryukov GV, Arold ST, Imielinski M, Theurillat JP et al. A landscape of driver mutations in melanoma. Cell 2012; 150: 251–263.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Yoshikawa Y, Sato A, Tsujimura T, Otsuki T, Fukuoka K, Hasegawa S et al. Biallelic germline and somatic mutations in malignant mesothelioma: multiple mutations in transcription regulators including mSWI/SNF genes. Int J Cancer 2015; 136: 560–571.

    CAS  PubMed  Google Scholar 

  8. Mehra R, Vats P, Kalyana-Sundaram S, Udager AM, Roh M, Alva A et al. Primary urethral clear-cell adenocarcinoma: comprehensive analysis by surgical pathology, cytopathology, and next-generation sequencing. Am J Pathol 2014; 184: 584–591.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Manceau G, Letouze E, Guichard C, Didelot A, Cazes A, Corte H et al. Recurrent inactivating mutations of ARID2 in non-small cell lung carcinoma. Int J Cancer 2013; 132: 2217–2221.

    Article  CAS  PubMed  Google Scholar 

  10. Buscarlet M, Krasteva V, Ho L, Simon C, Hebert J, Wilhelm B et al. Essential role of BRG, the ATPase subunit of BAF chromatin remodeling complexes, in leukemia maintenance. Blood 2014; 123: 1720–1728.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Shi J, Whyte WA, Zepeda-Mendoza CJ, Milazzo JP, Shen C, Roe JS et al. Role of SWI/SNF in acute leukemia maintenance and enhancer-mediated Myc regulation. Genes Dev 2013; 27: 2648–2662.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Madan V, Shyamsunder P, Han L, Mayakonda A, Nagata Y, Sundaresan J et al. Comprehensive mutational analysis of primary and relapse acute promyelocytic leukemia. Leukemia 2016; 30: 1672–1681.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Roberts CW, Orkin SH . The SWI/SNF complex—chromatin and cancer. Nat Rev Cancer 2004; 4: 133–142.

    Article  CAS  PubMed  Google Scholar 

  14. Wilson BG, Roberts CW . SWI/SNF nucleosome remodellers and cancer. Nat Rev Cancer 2011; 11: 481–492.

    Article  CAS  PubMed  Google Scholar 

  15. Neely KE, Workman JL . Histone acetylation and chromatin remodeling: which comes first? Mol Genet Metab 2002; 76: 1–5.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported by the National Institutes of Health (NIH, Bethesda, MD, USA) Grants RO1HL-082983 (to JPM), U54 RR019391 (to JPM), K24 HL-077522 (to JPM), a grant from the AA & MDS International Foundation (Rockville, MD, USA, to JPM and Cleveland OH, USA, to HM), the Robert Duggan Charitable Fund (Cleveland, OH, USA, to JPM), a grant from Edward P Evans Foundation (Cleveland, OH, USA, to JPM and MAS), Scott Hamilton CARES grant (Cleveland, OH, USA, to HM), Grant-in-Aids from the Ministry of Health, Labor and Welfare of Japan and KAKENHI (23249052, 22134006 and 21790907) (Tokyo, Japan, to SO) (15km0305018h0101, 16km0405110h0004 and 16H05338) (Kyoto, Japan, to HM), project for development of innovative research on cancer therapies (p-direct) (Tokyo, Japan, to SO), the Japan Society for the Promotion of Science (JSPS) through the ‘Funding Program for World-Leading Innovative R&D on Science and Technology’, initiated by the Council for Science and Technology Policy (CSTP) (Tokyo, Japan, to SO), project for cancer research and therapeutics evolution (P-CREATE) from Japan Agency for Medical Research and Development 16cm0106501h0001 (Kyoto Japan, to SO) and 16cm0106422h0001 (Kyoto Japan, to TY), National Aeronautics and Space Administration Grant NNJ13ZSA001N (Cleveland, OH, USA, to TR.) and a grant from The YASUDA Medical Foundation (Kyoto Japan, to HM). The results published here were partly based on data generated by The Cancer Genome Atlas pilot project established by the National Cancer Institute and National Human Genome Research Institute.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to H Makishima.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Supplementary Information accompanies this paper on the Leukemia website

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sakai, H., Hosono, N., Nakazawa, H. et al. A novel genetic and morphologic phenotype of ARID2-mediated myelodysplasia. Leukemia 32, 839–843 (2018). https://doi.org/10.1038/leu.2017.319

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2017.319

This article is cited by

Search

Quick links